Cover Image

Spontaneous Regression of Melanoma Metastases Associated with a Flare of Eczema

Shevya Manjri Tiwari, Alex Powell, Jason Dyke

Abstract


Introduction: Spontaneous regression of metastatic melanoma is a rare event with only a handful of cases documented in the world literature. The phenomenonremains much of an enigma however there is an increasing body of evidence to support an immunologic basis to regression.

Presentation of case: We report a case of spontaneous regression of widespread metastatic melanoma diagnosed radiologically in a 54 year old otherwise well Caucasian woman.  Regression of metastatic disease was first noted when the patient presented with a severe flare of otherwise well controlled atopic eczema. This continued to complete regression of all metastatic disease over a period of 26 months. She remained clinically well and disease free for three years, however subsequently developed new pulmonary nodules on routine PET scan suggestive of new metastases.

Conclusion:We discuss mechanisms of regression and hypothesize that this patient’s flare of eczema was related to T cell hyperactivity induced by tumour-associated-antigens produced by melanoma cellsCases of tumour regression and research into pathways involved in regression may offer insight into novel treatment options.


Keywords


Spontaneous regression; Metastatic melanoma; Immune sensitisation

Full Text:

PDF

References


Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: Review of the literature. Melanoma research. 2009, 19:275-282

Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, Lienard D, Gugerli O, Ferradini L, Robert C, Avril MF, Zitvogel L, Angevin E. Selective accumulation of mature dc-lamp+ dendritic cells in tumor sites is associated with efficient t-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer research. 2004, 64:2192-2198

Tran T, Burt D, Eapen L, Keller OR. Spontaneous regression of metastatic melanoma after inoculation with tetanus-diphtheria-pertussis vaccine. Current oncology. 2013, 20:e270-273

M M. Melanoma as a model tumour for immuno-oncology. Annals of oncology. 2012, 23:5

Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. Journal of the National Cancer Institute. 2001, 93:1047-1048

Tarhini AA, Kirkwood JM. Clinical and immunologic basis of interferon therapy in melanoma. Annals of the New York Academy of Sciences. 2009, 1182:47-57

Korman JB, Fisher DE. Developing melanoma therapeutics: Overview and update. Wiley interdisciplinary reviews. Systems biology and medicine. 2013, 5:257-271

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-pd-1) in melanoma. The New England journal of medicine. 2013, 369:134-144

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine. 2013, 369:122-133


Refbacks

  • There are currently no refbacks.


AJCC-REP (ISSN 2572-5742)Copyright © 2012-2020. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States